rs61747727

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 3P and 13B. PM1PP2BP4_StrongBP6BA1

The NM_014625.4(NPHS2):​c.725C>T​(p.Ala242Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00373 in 1,613,414 control chromosomes in the GnomAD database, including 209 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A242T) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.020 ( 110 hom., cov: 32)
Exomes 𝑓: 0.0020 ( 99 hom. )

Consequence

NPHS2
NM_014625.4 missense

Scores

3
8
7

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:1B:8

Conservation

PhyloP100: 3.50
Variant links:
Genes affected
NPHS2 (HGNC:13394): (NPHS2 stomatin family member, podocin) This gene encodes a protein that plays a role in the regulation of glomerular permeability. Mutations in this gene cause steroid-resistant nephrotic syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 4 uncertain in NM_014625.4
PP2
Missense variant in the gene, where a lot of missense mutations are associated with disease in ClinVar. The gene has 29 curated pathogenic missense variants (we use a threshold of 10). The gene has 4 curated benign missense variants. Gene score misZ: 0.68612 (below the threshold of 3.09). Trascript score misZ: 0.038296 (below the threshold of 3.09). GenCC associations: The gene is linked to familial idiopathic steroid-resistant nephrotic syndrome, nephrotic syndrome, type 2.
BP4
Computational evidence support a benign effect (MetaRNN=0.005230814).
BP6
Variant 1-179557040-G-A is Benign according to our data. Variant chr1-179557040-G-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 260429.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=1, Benign=7}.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.0688 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
NPHS2NM_014625.4 linkc.725C>T p.Ala242Val missense_variant Exon 5 of 8 ENST00000367615.9 NP_055440.1 Q9NP85-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
NPHS2ENST00000367615.9 linkc.725C>T p.Ala242Val missense_variant Exon 5 of 8 1 NM_014625.4 ENSP00000356587.4 Q9NP85-1
NPHS2ENST00000367616.4 linkc.535-2509C>T intron_variant Intron 4 of 6 1 ENSP00000356588.4 Q9NP85-2

Frequencies

GnomAD3 genomes
AF:
0.0204
AC:
3109
AN:
152196
Hom.:
109
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0711
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00792
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000176
Gnomad OTH
AF:
0.0139
GnomAD2 exomes
AF:
0.00536
AC:
1342
AN:
250452
AF XY:
0.00392
show subpopulations
Gnomad AFR exome
AF:
0.0731
Gnomad AMR exome
AF:
0.00354
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000115
Gnomad OTH exome
AF:
0.00262
GnomAD4 exome
AF:
0.00199
AC:
2906
AN:
1461100
Hom.:
99
Cov.:
31
AF XY:
0.00169
AC XY:
1225
AN XY:
726880
show subpopulations
Gnomad4 AFR exome
AF:
0.0718
AC:
2403
AN:
33452
Gnomad4 AMR exome
AF:
0.00392
AC:
175
AN:
44666
Gnomad4 ASJ exome
AF:
0.00
AC:
0
AN:
26122
Gnomad4 EAS exome
AF:
0.0000252
AC:
1
AN:
39680
Gnomad4 SAS exome
AF:
0.000197
AC:
17
AN:
86174
Gnomad4 FIN exome
AF:
0.00
AC:
0
AN:
53346
Gnomad4 NFE exome
AF:
0.0000360
AC:
40
AN:
1111558
Gnomad4 Remaining exome
AF:
0.00429
AC:
259
AN:
60338
Heterozygous variant carriers
0
138
276
413
551
689
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Exome Het
Exome Hom
Variant carriers
0
76
152
228
304
380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0204
AC:
3110
AN:
152314
Hom.:
110
Cov.:
32
AF XY:
0.0201
AC XY:
1494
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.0709
AC:
0.0709129
AN:
0.0709129
Gnomad4 AMR
AF:
0.00791
AC:
0.00790643
AN:
0.00790643
Gnomad4 ASJ
AF:
0.00
AC:
0
AN:
0
Gnomad4 EAS
AF:
0.00
AC:
0
AN:
0
Gnomad4 SAS
AF:
0.000207
AC:
0.000207125
AN:
0.000207125
Gnomad4 FIN
AF:
0.00
AC:
0
AN:
0
Gnomad4 NFE
AF:
0.000176
AC:
0.000176398
AN:
0.000176398
Gnomad4 OTH
AF:
0.0137
AC:
0.0137441
AN:
0.0137441
Heterozygous variant carriers
0
144
288
432
576
720
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Genome Het
Genome Hom
Variant carriers
0
36
72
108
144
180
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00531
Hom.:
76
Bravo
AF:
0.0241
ESP6500AA
AF:
0.0710
AC:
313
ESP6500EA
AF:
0.000116
AC:
1
ExAC
AF:
0.00650
AC:
789
Asia WGS
AF:
0.00289
AC:
10
AN:
3478
EpiCase
AF:
0.000109
EpiControl
AF:
0.0000593

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:8
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Benign:3
Jan 24, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 19, 2020
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 32691731, 30450462, 26211502, 12707396, 20981092) -

Jun 19, 2018
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nephrotic syndrome, type 2 Uncertain:1Benign:1
Apr 28, 2017
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. -

Jan 01, 2019
Institute of Human Genetics, University of Leipzig Medical Center
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:2
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 02, 2018
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: NPHS2 c.725C>T (p.Ala242Val) results in a non-conservative amino acid change located in the Band 7 domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0069 in 276216 control chromosomes, predominantly within the African subpopulation at a frequency of 0.073 in the gnomAD database, including 67 homozygotes. The observed variant frequency within African control individuals in the gnomAD database is approximately 41-fold above the estimated maximal expected allele frequency for a pathogenic variant in NPHS2 causing Nephrotic Syndrome, Type 2 phenotype (0.0018), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African origin. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as benign. Based on the evidence outlined above, the variant was classified as benign. -

Steroid-resistant nephrotic syndrome Benign:1
Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Focal segmental glomerulosclerosis Benign:1
Mar 14, 2022
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.32
BayesDel_addAF
Benign
-0.28
T
BayesDel_noAF
Benign
-0.12
CADD
Pathogenic
26
DANN
Pathogenic
1.0
DEOGEN2
Pathogenic
0.86
D
Eigen
Uncertain
0.68
Eigen_PC
Pathogenic
0.70
FATHMM_MKL
Uncertain
0.88
D
LIST_S2
Uncertain
0.90
D
MetaRNN
Benign
0.0052
T
MetaSVM
Uncertain
-0.068
T
MutationAssessor
Benign
1.9
L
PrimateAI
Benign
0.47
T
PROVEAN
Uncertain
-3.3
D
REVEL
Uncertain
0.64
Sift
Uncertain
0.010
D
Sift4G
Uncertain
0.036
D
Polyphen
0.99
D
Vest4
0.49
MVP
0.89
MPC
0.88
ClinPred
0.033
T
GERP RS
5.9
Varity_R
0.59
gMVP
0.68
Mutation Taster
=85/15
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs61747727; hg19: chr1-179526175; API